PL378195A1 - Inhibitory prezentacji antygenów przez cząsteczki MHC klasy II i sposoby ich zastosowania - Google Patents

Inhibitory prezentacji antygenów przez cząsteczki MHC klasy II i sposoby ich zastosowania

Info

Publication number
PL378195A1
PL378195A1 PL378195A PL37819504A PL378195A1 PL 378195 A1 PL378195 A1 PL 378195A1 PL 378195 A PL378195 A PL 378195A PL 37819504 A PL37819504 A PL 37819504A PL 378195 A1 PL378195 A1 PL 378195A1
Authority
PL
Poland
Prior art keywords
methods
inhibitors
molecules
mhc class
antigen presentation
Prior art date
Application number
PL378195A
Other languages
English (en)
Other versions
PL211458B1 (pl
Inventor
Gary L. Olson
Charles M. Cook
Christopher R. Self
Original Assignee
Provid Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provid Pharmaceuticals, Inc. filed Critical Provid Pharmaceuticals, Inc.
Publication of PL378195A1 publication Critical patent/PL378195A1/pl
Publication of PL211458B1 publication Critical patent/PL211458B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
PL378195A 2003-02-14 2004-02-13 Związki, kompozycja farmaceutyczna zawierająca je oraz zastosowanie związków PL211458B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44794903P 2003-02-14 2003-02-14

Publications (2)

Publication Number Publication Date
PL378195A1 true PL378195A1 (pl) 2006-03-06
PL211458B1 PL211458B1 (pl) 2012-05-31

Family

ID=32908515

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378195A PL211458B1 (pl) 2003-02-14 2004-02-13 Związki, kompozycja farmaceutyczna zawierająca je oraz zastosowanie związków

Country Status (11)

Country Link
US (3) US7439231B2 (pl)
EP (1) EP1605963B1 (pl)
AT (1) ATE533500T1 (pl)
AU (1) AU2004212954B2 (pl)
CA (1) CA2516080C (pl)
DK (1) DK1605963T3 (pl)
NO (1) NO20054238L (pl)
NZ (1) NZ542256A (pl)
PL (1) PL211458B1 (pl)
RU (1) RU2333219C2 (pl)
WO (1) WO2004073625A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE533500T1 (de) * 2003-02-14 2011-12-15 Provid Pharmaceuticals Inc Hemmer der antigenpräsentation über mhc-klasse-ii-moleküle und verwendungsverfahren dafür
EP2134176A4 (en) * 2007-03-30 2012-08-29 Brigham & Womens Hospital COMPOUNDS AND METHODS FOR ENHANCING MHC CLASS II THERAPIES
WO2009073168A1 (en) * 2007-12-03 2009-06-11 Provid Pharmaceuticals, Inc. Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof
EP2655395B1 (en) 2010-12-23 2018-03-07 Universiteit Gent Method for cross-linking peptides
KR20230024419A (ko) 2020-06-25 2023-02-20 휴먼웰 파마슈티컬 유에스 의학적 장애 치료용 펩티드
EP4308585A1 (en) * 2021-03-19 2024-01-24 Provid Pharmaceuticals Inc. Inhibitors of antigen presentation by mhc class ii hla-drb1*15:01 molecules with enhanced metabolic stability
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US6036957A (en) 1990-03-30 2000-03-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
KR960700739A (ko) 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
DE4340111A1 (de) * 1993-11-22 1995-05-24 Schering Ag Tumor-Nekrose-Faktor-alpha inaktivierende Peptide
DE4342846A1 (de) * 1993-12-10 1995-06-14 Schering Ag Tumor-Nekrose-Faktor-alpha inaktivierende Peptide
US5585980A (en) * 1994-06-09 1996-12-17 International Business Machines Corporation Low friction device for an actuator arm of a disk drive
US5559114A (en) * 1994-12-16 1996-09-24 Exley; Ray W. Treatment of autoimmune disease using 2-amino purine derivatives
US5874531A (en) 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5624902A (en) * 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
CA2226017A1 (en) * 1995-06-29 1997-01-16 Thomas Jefferson University Cd4-derived peptides that inhibit immune responses
FR2753707B1 (fr) * 1996-09-23 1998-12-11 Complexes nucleopeptidiques, compositions cosmetologiques et pharmaceutiques les contenant et utilisations
GB9621836D0 (en) 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
GB9624562D0 (en) 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
US6891046B2 (en) 2000-04-26 2005-05-10 Smith, Iii Amos B. Solution and solid phase synthesis of pyrrolinones and polypyrrolinones
JP2005533753A (ja) 2002-03-22 2005-11-10 ゲーペーツェー バイオテック アーゲー 免疫抑制化合物、それに関する方法及び使用法
ATE533500T1 (de) * 2003-02-14 2011-12-15 Provid Pharmaceuticals Inc Hemmer der antigenpräsentation über mhc-klasse-ii-moleküle und verwendungsverfahren dafür

Also Published As

Publication number Publication date
RU2005128549A (ru) 2006-02-10
DK1605963T3 (da) 2012-02-06
US8222215B2 (en) 2012-07-17
US20040162242A1 (en) 2004-08-19
CA2516080A1 (en) 2004-09-02
US20090111755A1 (en) 2009-04-30
WO2004073625A2 (en) 2004-09-02
CA2516080C (en) 2021-11-02
EP1605963A4 (en) 2007-02-14
AU2004212954A1 (en) 2004-09-02
US20120252734A1 (en) 2012-10-04
NO20054238L (no) 2005-11-11
EP1605963B1 (en) 2011-11-16
US8598312B2 (en) 2013-12-03
WO2004073625A3 (en) 2005-01-20
RU2333219C2 (ru) 2008-09-10
US7439231B2 (en) 2008-10-21
NZ542256A (en) 2009-05-31
ATE533500T1 (de) 2011-12-15
AU2004212954B2 (en) 2008-07-17
NO20054238D0 (no) 2005-09-13
PL211458B1 (pl) 2012-05-31
EP1605963A2 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
PH12014500053A1 (en) Proteasome inhibitors
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
TW200510416A (en) P38 inhibitors and methods of use thereof
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
PH12015501192A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
MY149957A (en) Heterocyclic inhibitors of mek and methods of use thereof
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GEP20125565B (en) Lactam compounds and their pharmaceutical use
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
NO20054238L (no) Inhibitorer av antigenpresentasjon ved MHC klasse II-molekyler og fremgangsmate for anvendelse av disse
TW200740808A (en) Inhibiteurs de proteines kinases
MXPA05003718A (es) Compuestos x-nitro, sus composiciones farmaceuticas y sus usos.
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
DK1931735T3 (da) Texaphyrinmetalkomplekser med høj renhed
MY180594A (en) Proteasome inhibitors
EA201791835A2 (ru) Ингибиторы протеасом